Levetiracetam in neonatal seizures as first-line treatment: A prospective study

Giovanna Vitaliti, Raffaele Falsaperla, Laura Mauceri, Cátia Romano, Piero Pavone, Nazgol Motamed-Gorji, Nassim Matin, Riccardo Lubrano, Giovanni Corsello

Journal of Pediatric Neurosciences · 2017 · 47 citations · 19 references

Concepts

Abstract

AIM OF THE STUDY: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. MATERIALS AND METHODS: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. RESULTS: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed. CONCLUSIONS: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.

References

19